Properties of Materials Used in Single-Use Flexible Containers: Requirements and Analysis - - BioPharm International


Properties of Materials Used in Single-Use Flexible Containers: Requirements and Analysis

BioPharm International

Figure 1. An example of a polymeric film. The outer layer (1) is made of PET, a clear protective polymer; the PA layer (2) gives mechanical strength; the EVOH layer (4) reduces gas transmission; and the fluid contact layer (5) is made of medical grade ULDPE. The four layers are laminated and the adhesion strength between layers is provided by a thermoset polymer layer (3).
The film structure can be laminated, co-extruded, or a combination of the two. In laminated films, all film layers are extruded separately and are bonded together by a thermoset adhesive. In co-extruded films, the film is manufactured in a single-step operation in which the film layers are bonded together by a tacky thermoplastic polymer. These two manufacturing techniques can be combined. Figure 1 shows the structure of a sample polymeric film.

Required testing and validation

Testing and validation requirements for films used in disposable equipment should be established by carrying out a risk analysis for each application. Product specifications, both technical and regulatory, depend on the level of safety required for each step in which the single-use products will be used. Applications such as final drug packaging obviously need more guarantees than initial formulation applications, after which further purification and sterilization steps are performed. For every application, an appropriate level of requirements and testing must be chosen.

Test conditions often are treated as variable parameters in the standards and are left to the convenience of the users. The choice of testing parameters must be driven by the application. Organizations such as the Bio-Process Systems Alliance (BPSA) are currently working on publishing a set of guidelines to help define these test conditions.3

Regulatory Requirements

The regulatory requirements that apply to films used in disposable equipment fall into several broad categories:

Biocompatibility requirements. 4–9 The biocompatibility requirements of a material depend on how it will be used within the process (e.g., media kitchen versus purification) and vicinity to the human body.

Sterility requirements. 10 The sterility requirements of a film clearly depend on the sterility requirements of the application. If a sterilization step is carried out after the use of a disposable container, that container may not need to be sterile.

Contamination requirements. 11,12 The contamination requirements of a film depend on the cleanliness requirements of the application. If a filtration step is carried out after the use of a disposable container, the actual particle contamination level in the disposable container may not need to be that low.

Endotoxins. 13,14 Regardless of the application, endotoxin requirements must be met, although the levels at which the actual limits are set can vary. It is important to note that the traditional methods for removing pyrogens cannot be performed in disposable equipment, because the high temperatures required would be detrimental to the polymeric nature of the materials used.

Container requirements. 15–18 Few current standards for disposables address the containers themselves, and those that exist mainly deal with the use of disposable bags for drug delivery. Only some of the existing standards are relevant for bioprocessing applications, and must be adapted to the bag configurations (e.g., sizes, tubes, connectors) used in processing. Risk analysis is necessary to identify the relevant tests, methods, and specifications for any container under study.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here